​Please complete the form, select from options below and we'll send you a quote!

“We have been using Protalizer for about 6 months or so. Protalizer has become our go-to package for much of our analyses of complex protein mixtures, especially when performing Label-Free quantification and Data-Independent Acquisition analysis. The normalization routines are highly innovative and allow us to validate our results with great ease. The analytical results are presented in an exceptionally understandable and well-organized format. We can summarize key metrics rapidly whereas our previous workflows would take many hours. This package has set a new bar in terms of ease of use and convenience. New users in the lab are able to use Protalizer within 1 day of training. However, the one key feature of the package is the accessibility of the support staff and their willingness to incorporate new ideas and accommodate specific requests. Their team is very knowledgeable and are always happy to look at our results and provide helpful feedback. We are really excited about Protalizer and will continue to use it routinely.”-- Michael M. Rosenblatt, PhD, Group Leader, MS Reagents, Promega Corporation

Advanced DIA proteomics with Protalizer represents a practical way for our lab to quantify nearly as many proteins as is currently possible with RNA-seq in a high-throughput and quantitative manner. I strongly recommend this program for any lab doing mass spectrometry-based proteomics."-- Michelle Olsen, PhD., Associate Professor, Virginia Tech

"The user-friendly interface and simple reports that Protalizer provides have greatly accelerated our ability to provide meaningful and understandable proteomics' results to our biological collaborators. Importantly, we can now spend more time generating and validating mass spectrometry findings and less time interpreting and reformatting the results."​— Jeremy L. Norris, PhD; Managing Director, National Resource for Imaging Mass Spectrometry; Associate Professor, Department of Biochemistry, Vanderbilt University School of Medicine

"The high sensitivity proteomics work and the data analysis of the proteomics results by Vulcan Analytical's software and experts were extremely useful for dual R&D programs nearing lead drug clinical candidate selection. Our company, DiscoveryBioMed, Inc., now has a clear idea about mechanism of action of the lead drug in both programs and the data are consistent with past internal work using kinase and other dot blot arrays. Also and equally important, the data are consistent with the literature regarding possible MoA."-- Erik Schwiebert, PhD, CEO Discovery BioMed, Inc.